B

BeOne

Global oncology therapeutics discovery, development, manufacturing

Director Global Digital & Technology Systems

Full-TimeUpdated on 10/1/2026
$172.5k - $232.5k/yr+ Annual bonus + Discretionary equity awards + Employee Stock Purchase Plan
Expert
Bachelor's
Remote in USA
RemoteRemote within the US, with travel of less than 15%.

About the job

Requirements
  • At least 10 years of experience working on validated applications in a pharmaceutical or regulated environment, primarily clinical applications or systems management, especially in Clinical Trial Management Systems, electronic Trial Master File, Interactive Response Technology, Electronic Data Capture, or Site Selection and Startup management.
  • At least 8 years of experience working in a GxP or regulated environment with a strong understanding of System Life Cycle methodology, 21 CFR Part 11, and Good Automated Manufacturing Practice principles.
  • At least 5 years of senior-level leadership experience managing a team of direct reports and associate staff.
  • Proven experience overseeing the direction, planning, installation, implementation, and maintenance of software solutions, especially in SaaS or hybrid-cloud environments.
  • Working knowledge of Office 365, Active Directory technology and schema, and SaaS-to-SaaS application integration frameworks.
  • Working knowledge of Infrastructure as a Service, Amazon Web Services, Azure, Platform as a Service, and Software as a Service architectures and technology options.
  • Extensive experience in business and technical analysis, including developing requirements and translating them into data-driven and technical solutions.
  • Strong expertise in data management practices, including data integrity, accuracy, and reliability.
  • Significant experience delivering technical projects and managing multiple initiatives across diverse functions in a global environment.
  • A Bachelor's Degree in Computer Science or Information Technology.
  • Ability to quickly learn and adapt to several technology areas.
  • Strong process improvement skills.
  • Ability to communicate ideas in both technical and user-friendly language.
  • Proven business and technology skills with success providing customer-oriented technology solutions.
  • Ability to manage team members at global sites, including employees and contingent workers, through coaching, training, and professional development.
Responsibilities
  • Own the end-to-end system management lifecycle for the portfolio of external systems and solutions used by Global Clinical Operations.
  • Be accountable for the entire lifecycle management of all external Global Clinical Operations applications and platforms.
  • Implement and deliver systems, applications, and projects that meet Global Clinical Operations business needs.
  • Provide data, digital, and technology systems expertise to Global Clinical Operations stakeholders.
  • Coordinate and drive system maintenance, including security patching, version upgrades, enhancements, and configuration changes.
  • Collaborate with Global Clinical Operations and Global Research and Development Technology Solutions leadership to develop long-term strategies for external system enhancements and technology investments.
  • Partner with stakeholders and subject matter experts to develop business cases that justify and prioritize system initiatives.
  • Develop and manage the budget for external systems.
  • Ensure data integrity, security, and proper governance of information processed through external systems.
  • Coordinate and manage incident response for external system issues, including timely resolution and stakeholder communication.
  • Create and maintain documentation related to system architecture, functionality, and operational procedures.
  • Provide guidance and support to end users and facilitate training programs.
  • Identify risks related to Global Clinical Operations external systems, establish mitigation strategies, and ensure compliance with regulatory requirements.
  • Engage and collaborate with third-party vendors, service providers, and stakeholders to manage contracts, performance, and service-level agreements.
  • Foster collaboration across functions to integrate clinical systems with corporate enterprise systems.
  • Collaborate with Technology and Systems Engineering and Global Research and Development Technology Solutions Operations teams to deliver solutions within allocated budgets.
  • Ensure Global Clinical Operations systems and data platforms adhere to pharmaceutical industry regulations, security policies, and enterprise policies.
  • Liaise with computer system vendors, Information Technology partners, audit, and compliance teams to coordinate system implementation and change activities.
  • Support requirements management, solutioning, build, implementation, and administration of global development platforms, master data, and system interfaces.
  • Lead, mentor, and manage the Global Clinical Operations Systems Management team.
  • Foster a culture of innovation, accountability, and professional development.
  • Ensure the team embeds computer system validation, compliance, and health authority requirements into operational activities.
  • Collaborate with Research and Development functions on standards and best practices.
  • Engage with peers to define, sponsor, and execute continuous improvements.
  • Translate long-term clinical objectives into a multi-year system capability roadmap for external Global Clinical Operations systems.
  • Translate complex clinical workflows into structural, technical system, and data requirements.
  • Align clinical functions, internal Information Technology groups, and external vendors around external system standards.
  • Manage end-to-end delivery of digital and technology systems and solutions from scoping and vendor selection through deployment and value realization.
  • Develop a Global Clinical Operations data, digital, and technology roadmap for external systems.
  • Create business capability maps showing current-state and future-state technical capabilities and relationships across functions.
  • Create product requirements documents with prioritized functional and technical requirement backlogs.
  • Create conceptual design and specification documents for Global Clinical Operations platforms and system interactions.
  • Prepare vendor selection and proof-of-concept briefs, including technical evaluations and business cases.
  • Develop platform operating models with Systems Engineering and Global Technology Services to keep platforms stable, highly available, and optimized during production.
  • Deliver and launch annual operating plan projects based on approved requirements, specifications, development activities, and implementation plans.
Desired Qualifications
  • Knowledge of Infrastructure as a Service, Amazon Web Services, Azure, Platform as a Service, and Software as a Service architectures and technology options.
  • Understanding of how artificial intelligence solutions integrate within external systems and platforms, including machine learning lifecycles, foundational models, and AI-ready data.

About the company

BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dongcheng District, China

Founded

2010

Get referred to BeOne

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 25, 2026 FDA approval expanded TEVIMBRA in first-line HER2-positive gastroesophageal cancer.
  • August 31, 2026 Phase 3 survival data strengthened ZIIHERA-containing regimens.
  • Q2 2026 revenue hit $1.7 billion; management raised 2026 guidance to $6.8 billion.

What critics are saying

  • BeOne accepted developed-market pricing parity and Medicaid rebates on future U.S. approvals.
  • Zydus' BRUKINSA ANDA lawsuit targets patents; a 2034 composition patent remains the fortress.
  • AbbVie's trade-secrets case over BGB-16673 still threatens the BTK-degrader franchise.

What makes BeOne unique

  • BeOne built 35-plus assets and 93 trials across 1,100 U.S. sites by September 2026.
  • BRUKINSA dominates revenue, with 2026 global sales above $1.2 billion quarterly.
  • Hopewell, New Jersey gives BeOne U.S. manufacturing, R&D, and packaging capacity.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

Wellness Program

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

↑ 8%

1 year growth

↓ -6%

2 year growth

↓ -1%
Yahoo Finance
Sep 4th, 2026
BeOne secures US pharma-tariff exemption after $1B+ manufacturing investment, but pricing concessions raise margin concerns

BeOne Medicines secured an exemption from Section 232 pharmaceutical tariffs through a voluntary agreement with the US government. The deal recognises over $1 billion in US manufacturing investment, including a $300 million expansion in Hopewell, New Jersey. The exemption protects BeOne from import duties on patented pharmaceuticals and ingredients. However, the company committed to pricing future FDA-approved medicines in line with other developed markets and participating in the Medicaid GENEROUS Model, which uses supplemental rebates. The Hopewell expansion will add small-molecule manufacturing and packaging capacity, creating approximately 120 full-time jobs. The facility will support a portfolio of more than 35 assets. Whilst the tariff exemption reduces supply-chain risk, international reference pricing commitments could limit pricing flexibility for future oncology medicines. Neither the tariff savings nor the financial impact of pricing concessions was disclosed.

Yahoo Finance
Aug 13th, 2026
Revolution Medicines shares rise 6.2% on BeOne-funded Phase 3 RAS(ON) deal

Revolution Medicines has partnered with BeOne Medicines in a multi-part collaboration combining BeOne's oncology assets with Revolution's four clinical RAS(ON) inhibitors. The August 2026 deal grants BeOne exclusive development and commercialisation rights in select Asian markets and commits BeOne to fund a global Phase 3 trial. Revolution Medicines reported a net loss of $644.37 million in Q2 2026 and $1.1 billion over six months. The company currently generates no revenue but projects $2.3 billion in revenue and $402.5 million in earnings by 2029. The partnership shifts near-term risk by offloading Phase 3 costs whilst providing access to milestone and royalty potential. However, the core investment case remains unchanged: regulatory progress and commercialisation of daraxonrasib, with trial execution and spending presenting the biggest risks.

Yahoo Finance
Aug 5th, 2026
BeOne Medicines Q2 revenue up 30% to $1.7B as BRUKINSA sales top $1.2B globally

BeOne Medicines reported second-quarter revenue of $1.7 billion, up 30% year over year, with GAAP earnings per ADS rising 144% to $2.05. The company's BTK inhibitor BRUKINSA generated more than $1.2 billion in global sales, increasing 31% from the prior year. The company raised its 2026 revenue guidance to CNY 6.6 billion–CNY 6.8 billion and expects GAAP operating income of CNY 1 billion–CNY 1.1 billion. Free cash flow doubled year over year to CNY 435 million. BeOne received FDA approval for Beqalzi in relapsed or refractory mantle cell lymphoma and reported positive Phase III results for a chemotherapy-free BRUKINSA regimen. US BRUKINSA sales totalled $893 million, up 31%, driven by demand in chronic lymphocytic leukaemia and non-CLL indications.

Yahoo Finance
Jul 23rd, 2026
BeOne CEO sells $34.6M in stock while retaining 50M+ shares

John Oyler, chief executive officer of BeOne Medicines AG, sold 109,713 American Depositary Shares worth $34.6 million on 20 and 21 July 2026, according to SEC filings. The transactions were executed under a Rule 10b5-1 trading plan adopted in March 2026. Despite the sale, Oyler retains a substantial ownership position exceeding 50.4 million total shares through various holdings. These include 28.2 million shares held through Oyler Investment LLC and 9.5 million shares in a Roth IRA account. The shares were sold at a weighted average price of $315.28. BeOne Medicines is a commercial-stage oncology biopharmaceutical company with $5.7 billion in trailing twelve-month revenue and a market capitalisation of $34.2 billion.

PR Newswire
Jul 21st, 2026
Seegene USA receives FDA emergency authorisation for first multiplex PCR test to diagnose viral causes of ulcerative skin lesions

Seegene USA has received Emergency Use Authorization from the FDA for its Allplex HSV-1&2/VZV/MPXV Assay, a multiplex real-time PCR test that simultaneously detects herpes simplex virus types 1 and 2, varicella-zoster virus, and monkeypox virus. It is the first multiplex PCR test designed to support differential diagnosis of viral causes of ulcerative skin lesions in the US market. These pathogens often present with similar clinical symptoms that are difficult to distinguish visually. Research presented at the 2024 Clinical Virology Symposium found that a multiplex PCR assay identified HSV, VZV, or MPXV in 54 out of 966 samples that had previously tested negative using single-pathogen methods. The assay was developed using Seegene's proprietary multiplex PCR technologies and automated product development platform.